|
|
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
|
NGM Biopharmaceuticals, Inc. is dedicated
to the discovery and development of transformational medicines. Relying on human
clinical and genetic observations, the Company has established a unique research
and discovery platform to identify and validate novel targets and factors that
impact the underlying etiology of metabolic diseases. NGM’s strategy is to
elucidate the roles of these previously unidentified or unexplored hormones,
receptors and factors in the systemic regulation of metabolism. |
|
RECENT NEWS NGM Biopharmaceuticals Names William J. Rieflin Chief Executive Officer and Director October 05, 2010 NGM Biopharmaceuticals Raises $51 Million in Series B Financing and Appoints New Board Member March 15, 2010 NGM Appoints Dr. Arthur D. Levinson, former Genentech CEO, to its Board of Directors October 21, 2009
NGM Appoints Helen S. Kim as
September 1, 2009 |
![]() |